by Gabriela B. Gomez, Annick Borquez, Kelsey K. Case et al.
PLoS Med 10(3): e1001401 (12 March 2013)
The findings of this study suggest that Pre-exposure Prophylaxis (PrEP) could be a cost-effective tool to reduce new HIV infections in some settings. However, the cost-effectiveness of PrEP is dependent upon cost, the epidemic context, program coverage and prioritization strategies, participants’ adherence to the drug regimen, and PrEP efficacy estimates. These findings will aid decision makers quantify and compare the reductions in HIV incidence that could be achieved by implementing a PrEP program.